{"id":249776,"date":"2023-10-10T00:00:00","date_gmt":"2023-10-10T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/concim0004-2023-biopharma-atopic-dermatitis-atopic-eczema-geographic\/"},"modified":"2026-03-31T10:31:58","modified_gmt":"2026-03-31T10:31:58","slug":"concim0004-2026-biopharma-atopic-dermatitis-atopic-eczema-geographic-focus-china-atopic-dermatitis-atopic-eczema","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concim0004-2026-biopharma-atopic-dermatitis-atopic-eczema-geographic-focus-china-atopic-dermatitis-atopic-eczema\/","title":{"rendered":"Atopic Dermatitis \/ Atopic Eczema &#8211; Geographic Focus: China &#8211; Atopic Dermatitis\/Atopic Eczema &#8211; China In-Depth (China )"},"content":{"rendered":"<p>Atopic dermatitis (<abbr title=\"atopic dermatitis\">AD<\/abbr>) is a chronic inflammatory skin disease characterized by pruritus and eczema that significantly affects patients\u2019 quality of life. It is traditionally treated with conventional topical and\/or systemic agents. Topicals are usually effective for mild cases but not for moderate to severe disease; topicals may also have suboptimal safety, tolerability, and compliance. Thus, there is significant unmet need for more-efficacious therapies for topical-refractory patients and for those with moderate to severe <abbr title=\"atopic dermatitis\">AD<\/abbr>. China\u2019s National Medical Products Administration (NMPA) has approved the targeted therapies Dupixent (Sanofi\u2019s dupilumab), Rinvoq (AbbVie\u2019s upadacitinib), and Cibinqo (Pfizer\u2019s abrocitinib) for moderate to severe <abbr title=\"atopic dermatitis\">AD<\/abbr>, and many other targeted therapies are in the pipeline. This report provides a comprehensive analysis of China\u2019s <abbr title=\"atopic dermatitis\">AD<\/abbr> patient populations, current disease management, lingering unmet needs, and the clinical and commercial potential of current and emerging drugs.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How large is China\u2019s drug-treatable <abbr title=\"atopic dermatitis\">AD<\/abbr> population, and how will the drug-treatment rate change over the forecast period?<\/li>\n<li>Which drugs are the most commercially relevant in China\u2019s <abbr title=\"atopic dermatitis\">AD<\/abbr> market and why?<\/li>\n<li>What are interviewed experts\u2019 insights into current treatments?<\/li>\n<li>What are the key unmet needs in the management of <abbr title=\"atopic dermatitis\">AD<\/abbr> in China?<\/li>\n<li>What are the key market access considerations, and how will they impact the uptake of emerging therapies for <abbr title=\"atopic dermatitis\">AD<\/abbr> in China?<\/li>\n<li>What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p>Geographies: China.<\/p>\n<p>Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with dermatologists and pediatricians.<\/p>\n<p>Epidemiology: Diagnosed prevalence of <abbr title=\"atopic dermatitis\">AD<\/abbr> in urban versus rural China; clinically relevant and market-relevant drug-treatable populations.<\/p>\n<p>Forecast:<b> <\/b>Ten-year, annualized, drug-level sales and patient shares of key <abbr title=\"atopic dermatitis\">AD<\/abbr> therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions.<\/p>\n<p>Emerging therapies: Phase III\/<abbr title=\"preregistered\">PR<\/abbr>: 7 agents; Phase II: 10 agents; coverage of select early-phase products.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p><em>China In-Depth <\/em>offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.<\/p>\n","protected":false},"template":"","class_list":["post-249776","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249776\/revisions"}],"predecessor-version":[{"id":389151,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249776\/revisions\/389151"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}